Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study.
biologic therapy
injection site reactions
psoriasis
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2023
2023
Historique:
received:
08
12
2022
accepted:
22
02
2023
entrez:
10
3
2023
pubmed:
11
3
2023
medline:
11
3
2023
Statut:
epublish
Résumé
Biologic selection for psoriasis treatment should take into account numerous factors including injection site reactions (ISRs) such as swelling at the injection site, pain, burning, erythema, all possibly reducing patient adherence. A 6-months observational real life study was performed involving psoriasis patients. Inclusion criteria were age ≥ 18 years, moderate-to-severe psoriasis diagnosis since at least 1 year, patients being on biologic treatment for psoriasis ≥ 6 months. A 14-item questionnaire was administered to all patients enrolled to assess whether the patient ever experienced ISRs after the injection of the biologic drug. 234 patients were included: 32.5% received an anti-TNF-alpha drug, 9.4% received anti-IL12/23, 32.5% received an anti-IL17, 25.6% received an anti-IL23. 51.2% of study population reported at least one symptom related to ISR. 35.9% of patients experienced pain, 31.6% swelling, 28.2% burning sensation and 17.9% erythema. 3.4% of the surveyed population experienced anxiety or fear of the biologic injection due to ISRs symptoms. The greater incidence of pain was registered in anti-TNF-alpha and anti-IL17 groups (47.4% and 42.1%, p<0.01). Ixekizumab proved to be the drug with the highest rate of patients experiencing pain (72.2%), burning (77.7%) and swelling (83.3%). No patients reported biologics discontinuation or delay for ISRs symptoms. Our study highlighted that each different class of biologics for psoriasis was linked to ISRs. These events are more frequently reported with anti-TNF-alpha and anti-IL17.
Sections du résumé
Background
UNASSIGNED
Biologic selection for psoriasis treatment should take into account numerous factors including injection site reactions (ISRs) such as swelling at the injection site, pain, burning, erythema, all possibly reducing patient adherence.
Methods
UNASSIGNED
A 6-months observational real life study was performed involving psoriasis patients. Inclusion criteria were age ≥ 18 years, moderate-to-severe psoriasis diagnosis since at least 1 year, patients being on biologic treatment for psoriasis ≥ 6 months. A 14-item questionnaire was administered to all patients enrolled to assess whether the patient ever experienced ISRs after the injection of the biologic drug.
Results
UNASSIGNED
234 patients were included: 32.5% received an anti-TNF-alpha drug, 9.4% received anti-IL12/23, 32.5% received an anti-IL17, 25.6% received an anti-IL23. 51.2% of study population reported at least one symptom related to ISR. 35.9% of patients experienced pain, 31.6% swelling, 28.2% burning sensation and 17.9% erythema. 3.4% of the surveyed population experienced anxiety or fear of the biologic injection due to ISRs symptoms. The greater incidence of pain was registered in anti-TNF-alpha and anti-IL17 groups (47.4% and 42.1%, p<0.01). Ixekizumab proved to be the drug with the highest rate of patients experiencing pain (72.2%), burning (77.7%) and swelling (83.3%). No patients reported biologics discontinuation or delay for ISRs symptoms.
Conclusion
UNASSIGNED
Our study highlighted that each different class of biologics for psoriasis was linked to ISRs. These events are more frequently reported with anti-TNF-alpha and anti-IL17.
Identifiants
pubmed: 36896374
doi: 10.2147/CCID.S400679
pii: 400679
pmc: PMC9989005
doi:
Types de publication
Journal Article
Langues
eng
Pagination
553-564Informations de copyright
© 2023 Megna et al.
Déclaration de conflit d'intérêts
Matteo Megna acted as a speaker or consultant for Abbvie, Novartis, Eli Lilly, Janssen, UCB, Amgen, Leo Pharma; Gabriella Fabbrocini acted as a speaker or consultant for Abbvie, Novartis, Eli Lilly, Janssen, UCB, Amgen, Leo Pharma, Almirall. The remaining authors report no conflicts of interest in this work.
Références
Biomedicines. 2021 Oct 15;9(10):
pubmed: 34680599
Dermatol Ther. 2019 Mar;32(2):e12817
pubmed: 30637967
J Clin Med. 2021 Mar 03;10(5):
pubmed: 33802255
J Dermatolog Treat. 2022 Sep;33(6):2813-2820
pubmed: 35603992
Dermatol Ther. 2022 Jul;35(7):e15524
pubmed: 35439341
J Drugs Dermatol. 2017 Jul 1;16(7):695-698
pubmed: 28697222
J Drugs Dermatol. 2018 Feb 1;17(2):200-206
pubmed: 29462229
J Dermatolog Treat. 2022 May;33(3):1511-1520
pubmed: 33535847
Psoriasis (Auckl). 2022 Jul 14;12:205-212
pubmed: 35859710
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e680-e682
pubmed: 32557847
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
Dermatol Ther (Heidelb). 2020 Feb;10(1):99-106
pubmed: 31734937
Dermatol Ther. 2022 Sep;35(9):e15667
pubmed: 35762107
Ital J Dermatol Venerol. 2022 Feb;157(Suppl. 1 to No. 1):1-78
pubmed: 35262308
Adv Ther. 2022 Jun;39(6):2862-2872
pubmed: 35449322
Ann Rheum Dis. 2018 Feb;77(2):228-233
pubmed: 29030361
Clin Rheumatol. 2018 Jul;37(7):1739-1741
pubmed: 29644570
Expert Opin Drug Saf. 2022 Dec;21(12):1445-1451
pubmed: 36527300
Psoriasis (Auckl). 2022 Jun 08;12:127-137
pubmed: 35707807
Expert Opin Drug Saf. 2023 Jan;22(1):25-41
pubmed: 36718762
J Dermatolog Treat. 2022 Aug;33(5):2560-2564
pubmed: 35098859
Dermatol Ther. 2022 Dec;35(12):e15941
pubmed: 36239544
Clin Exp Dermatol. 2022 Dec;47(12):2280-2282
pubmed: 35867020
Expert Opin Drug Saf. 2023 Jan;22(1):43-58
pubmed: 36718748
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e863-e864
pubmed: 35723893
Dermatol Ther. 2022 May;35(5):e15374
pubmed: 35147269
Dermatol Ther. 2022 Jan;35(1):e15214
pubmed: 34800070
Arch Dermatol Res. 2022 Aug;314(6):619-623
pubmed: 33609180
Adv Ther. 2019 Nov;36(11):2986-2996
pubmed: 31587143